[Consensus for the Diagnosis and Management of Extramedullary Plasmacytoma in China(2024)]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2024 Mar 25

PMID 38527832

Affiliations

Soon will be listed here.

Abstract

Extramedullary plasmacytoma (EMP) is a special type of malignant plasmacytosis, which is complex and heterogeneous. Most EMP patients have poor prognosis and lack a stratified prognostic system or ideal treatment strategy supported by evidence-based medical evidence, which cannot meet clinical needs. In order to improve the understanding of this disease entity, Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association and Chinese Myeloma Committee-Chinese Hematology Association developed the "Chinese Expert Consensus on the diagnosis and treatment of extramedullary plasmacytoma", which aims to standardize the clinical diagnosis and treatment of EMP and ultimately improve the overall survival of patients with plasmacytoma.

Citing Articles

Efficacy of the CV‑MED regimen in treating extramedullary involvement of multiple myeloma: A case report.

Gao J, Dong F, Zhang X, Jing H Oncol Lett. 2024; 28(6):612.

PMID: 39525606 PMC: 11544527. DOI: 10.3892/ol.2024.14745.

References

Gagelmann N, Eikema D, Iacobelli S, Koster L, Nahi H, Stoppa A . Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018; 103(5):890-897. PMC: 5927971. DOI: 10.3324/haematol.2017.178434. View

Rasche L, Schinke C, Maura F, Bauer M, Ashby C, Deshpande S . The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states. Nat Commun. 2022; 13(1):4517. PMC: 9349320. DOI: 10.1038/s41467-022-32145-y. View

Wang B, Zhao W, Chen Y, Cao X, Yang Y, Zhang Y . Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report. J Med Case Rep. 2022; 16(1):459. PMC: 9741775. DOI: 10.1186/s13256-022-03636-9. View

Nahi H, Genell A, Walinder G, Uttervall K, Juliusson G, Karin F . Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. Eur J Haematol. 2017; 99(3):216-222. DOI: 10.1111/ejh.12907. View

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R . Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica. 2019; 105(1):193-200. PMC: 6939525. DOI: 10.3324/haematol.2019.219139. View

Kumar S, Paiva B, Anderson K, Durie B, Landgren O, Moreau P . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346. DOI: 10.1016/S1470-2045(16)30206-6. View

Huynh T, Corre E, Lemonnier M, Dulery R, Marjanovic Z, Jaff N . Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease. Leuk Lymphoma. 2021; 62(9):2235-2241. DOI: 10.1080/10428194.2021.1907373. View

Slater D . The new World Health Organization classification of haematopoietic and lymphoid tumours: a dermatopathological perspective. Br J Dermatol. 2002; 147(4):633-9. DOI: 10.1046/j.1365-2133.2002.05050.x. View

Ghiassi-Nejad Z, Ru M, Moshier E, Chang S, Jagannath S, Dharmarajan K . Overall Survival Trends and Clinical Characteristics of Plasmacytoma in the United States: A National Cancer Database Analysis. Clin Lymphoma Myeloma Leuk. 2019; 19(5):310-319. PMC: 6555681. DOI: 10.1016/j.clml.2019.01.004. View

10.

Bhutani M, Foureau D, Atrash S, Voorhees P, Usmani S . Extramedullary multiple myeloma. Leukemia. 2019; 34(1):1-20. DOI: 10.1038/s41375-019-0660-0. View

11.

Gagelmann N, Eikema D, Koster L, Caillot D, Pioltelli P, Lleonart J . Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and.... Biol Blood Marrow Transplant. 2019; 25(11):2134-2142. DOI: 10.1016/j.bbmt.2019.07.004. View

12.

Caers J, Paiva B, Zamagni E, Leleu X, Blade J, Kristinsson S . Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018; 11(1):10. PMC: 5771205. DOI: 10.1186/s13045-017-0549-1. View

13.

Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View

14.

Rosinol L, Beksac M, Zamagni E, van de Donk N, Anderson K, Badros A . Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021; 194(3):496-507. DOI: 10.1111/bjh.17338. View

15.

Dingli D, Ailawadhi S, Bergsagel P, Buadi F, Dispenzieri A, Fonseca R . Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017; 92(4):578-598. PMC: 5554888. DOI: 10.1016/j.mayocp.2017.01.003. View

16.

Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V . Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016; 91(6):575-80. PMC: 5502095. DOI: 10.1002/ajh.24351. View

17.

Gerry D, Lentsch E . Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck. Otolaryngol Head Neck Surg. 2013; 148(6):974-81. DOI: 10.1177/0194599813481334. View

18.

Lakshman A, Paul Singh P, Rajkumar S, Dispenzieri A, Lacy M, Gertz M . Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol. 2017; 93(2):179-186. DOI: 10.1002/ajh.24954. View

19.

Goyal G, Bartley A, Funni S, Inselman J, Shah N, Marshall A . Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset. Leukemia. 2018; 32(6):1414-1420. PMC: 6522261. DOI: 10.1038/s41375-018-0099-8. View

20.

Pham A, Mahindra A . Solitary Plasmacytoma: a Review of Diagnosis and Management. Curr Hematol Malig Rep. 2019; 14(2):63-69. DOI: 10.1007/s11899-019-00499-8. View